| 6.57 0.16 (2.5%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.4 | 1-year : | 9.26 |
| Resists | First : | 7.19 | Second : | 7.92 |
| Pivot price | 6.76  |
|||
| Supports | First : | 6 | Second : | 4.99 |
| MAs | MA(5) : | 6.75  |
MA(20) : | 6.88 |
| MA(100) : | 6.98 |
MA(250) : | 6.11 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 37.3 |
D(3) : | 45 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 8.86 | Low : | 3.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SLDB ] has closed above bottom band by 35.6%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.78 - 6.82 | 6.82 - 6.85 |
| Low: | 6.27 - 6.31 | 6.31 - 6.34 |
| Close: | 6.52 - 6.57 | 6.57 - 6.62 |
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Mon, 08 Jun 2026
SLDB: Advanced gene therapy programs show strong safety, efficacy, and expanding market potential - TradingView
Mon, 08 Jun 2026
Solid Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Sat, 06 Jun 2026
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
Fri, 05 Jun 2026
SLDB (NASDAQ: SLDB) supplement lists updated selling stockholders and holdings - Stock Titan
Mon, 01 Jun 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Mon, 01 Jun 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 98 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 101.6 (%) |
| Shares Short | 9,100 (K) |
| Shares Short P.Month | 9,440 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -57.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -172 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -3.43 |
| PEG Ratio | 0 |
| Price to Book value | 1.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|